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Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP 
and toxicity after radiotherapy in 5,456 breast and prostate cancer patients 
 
Abstract 
Purpose: Several small studies have indicated that the ATM rs1801516 SNP is associated with risk of normal tissue 
toxicity after radiotherapy. However, the findings have not been consistent. In order to test this SNP in a well-
powered study, an individual patient data meta-analysis was carried out by the International Radiogenomics 
Consortium. 
Material and methods: The analysis included 5,456 patients from 17 different cohorts. 2,759 patients were given 
radiotherapy for breast cancer and 2,697 for prostate cancer. Eight toxicity scores (overall toxicity, acute toxicity, late 
toxicity, acute skin toxicity, acute rectal toxicity, telangiectasia, fibrosis and late rectal toxicity) were analyzed. 
Adjustments were made for treatment and patient related factors with potential impact on the risk of toxicity. 
Results: For all endpoints except late rectal toxicity, a significantly increased risk of toxicity was found for carriers of 
the minor (Asn) allele with odds of approximately 1.5 for acute toxicity and 1.2 for late toxicity. The results were 
consistent with a co-dominant pattern of inheritance. 
Conclusion: This study convincingly showed a significant association between the ATM rs1801516 Asn allele and 
increased risk of radiation-induced normal tissue toxicity. 
 
Background 
Since 2003, more than 100 published studies have tried to link single nucleotide polymorphisms (SNPs) to the risk of 
normal tissue toxicity after radiotherapy [1]. Except for 7 studies [2-8], all took a candidate gene approach. One of the 
main purposes of this research is to identify genetic factors that can be used to establish a predictive assay for normal 
tissue radiosensitivity [9]. The vast majority of these studies has been underpowered to detect the small effect sizes 
usually found for SNPs [10]. Even though numerous significant associations were reported [10-12], only very few of 
these have been independently confirmed [13,14]. The gene product of ATM plays a crucial role in biological response 
to ionizing radiation. It is involved in the detection of DNA double strand breaks and initiation of pathways that lead to 
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cycle arrest followed by DNA repair or apoptosis [15]. Patients having a truncating mutation in both copies of the ATM 
gene suffer from the rare syndrome ataxia telangiectasia [16]. It has been reported that these patients develop 
devastating normal tissue toxicity if given radiotherapy [17]. At the turn of the millennium, ATM mutations were 
among the first to be investigated for a possible association with normal tissue radiosensitivity. Several studies looked 
for an association between heterozygocity for truncating ATM mutations and risk of normal tissue toxicity after 
radiotherapy (reviewed in [18]). These studies did not show any significant association. However, the limited size of 
the studies should be taken into account in the interpretation of these results. Numerous studies have investigated 
the impact of SNPs in ATM upon normal tissue toxicity. The SNP designated rs1801516 (c.5557G>A, p.Asp1853Asn) is 
among the ATM SNPs that have been most extensively investigated. This SNP results in a non-conservative amino acid 
substitution from an aspartic acid to an asparagine in exon 37 (NM_000051.3). A number of relatively small studies 
indicated that the minor allele of this SNP increases the risk of normal tissue toxicity after radiotherapy (reviewed in 
[19-21]). Nevertheless, the findings have not been entirely consistent. Three literature based meta-analyses have 
addressed the impact of the rs1801516 SNP upon radiation-induced normal tissue toxicity. Two of these meta-
analyses demonstrated a significantly increased risk of acute toxicity (N=1,588)[20] and radiation-induced fibrosis 
(N=2,000) [21] respectively among carriers of the minor (Asn) allele whereas the largest of these meta-analyses 
(N=2,127) did not show a significant association between the SNP and risk of normal tissue toxicity in broader terms 
[19]. In order to bring this SNP to a test in the setting of a well-powered investigation, the International 
Radiogenomics Consortium (RgC) [22] conducted an individual patient data meta-analysis. With the intention to 
minimize the effect of publication bias, the analysis included published as well as unpublished data. In this paper, we 
intended the best possible adherence to the STROGAR guidelines for reporting results of genetic association studies in 
radiogenomics [23]. 
 
Material and methods 
Study cohorts 
Between January 2013 and September 2014, members of the RgC were encouraged to submit patient series 
(published as well as unpublished) for a meta-analysis addressing the impact of the ATM rs1801516 SNP upon normal 
tissue radiosensitivity. As part of this process, 17 cohorts (6 for prostate cancer and 11 for breast cancer) were 
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submitted and all of these were included in the present meta-analysis. The cohorts summed up to 5,624 patients. 
However, 168 patients were excluded from the analysis due to missing genotype data (n=31) or missing toxicity data 
(n=137) leaving 5,456 patients to be included in the analysis (Table 1). Consort diagram of the analysis is provided in 
Supplementary Figure S1. For three of the cohorts, the rs1801516 SNP was indirectly genotyped by means of the 
rs4988023 SNP (Table 1). This SNP is in strong linkage with the rs1801516 SNP (r
2
=1) [11] and we therefore consider it 
an appropriate surrogate for the rs1801516 SNP. A brief description of the cohorts, genotyping procedures and 
scoring of the normal tissue reactions is given in Supplementary Text File 1 and in [5,6,8,13,14] and [24-30]. In addition 
to genotype and toxicity data, recordings of covariates with potential influence on radiation response were collected.  
 
Statistical analysis 
Overall analytical strategy 
The strategy for statistical analysis was determined prior to data analysis. It was decided to analyze the dataset with 
regard to so called STAT scores (see below) for overall toxicity, acute toxicity and late toxicity. In addition, it was 
decided to analyze the dataset with regard to separate endpoints for which data were available from at least 1,000 
patients. This was the case for acute skin toxicity (n=1,357), acute rectal toxicity (n=1,005), telangiectasia (n=2,404), 
fibrosis (n=2,457) and late rectal toxicity (n=2,215).  
The following criteria were used to determine which data should be included in the analysis: 
• Toxicity recorded during treatment or within a period of 3 months after treatment was included in the STAT 
scores for acute toxicity 
• Toxicity recorded 2 years or more from the end of treatment  was included in the STAT scores for late toxicity 
• For cohorts that were scored more than once, the recordings closest to the end of treatment were used for 
the analysis of acute toxicity and the recordings at least 2 years after treatment that had the highest 
proportion of non-missing values were used for late toxicity 
• All toxicity recordings were included in the STAT score calculations except for endpoints with a frequency of 
events below 5% (an event was defined as a toxicity score different from zero) 
• For the 5 ‘separate endpoints’, data series with event frequencies below 5% were accepted 
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Using these criteria, 31,006 individual toxicity measurements were eligible for the meta-analysis. An overview of the 
data that were included in the analysis is provided in Table 1 and a more elaborate description is given in 
Supplementary Table S1. Recordings of covariates with potential influence on the normal tissue outcome were 
available for 3,666 patients from 13 cohorts (Supplementary Table S2). A total of 50,458 covariate observations were 
eligible for the analysis. 
 
Z score conversion   
In order to obtain a summary measure of toxicity across different endpoints, scoring systems and institutions, all 
analyzed toxicity recordings were converted into Z scores using the equation  
Zk = (Sk – mean) / standard deviation 
in which Zk designates the Z score for a patient k having the toxicity score Sk and the mean and standard deviation 
taken  over all cases in the cohort with non-missing scores for that endpoint. This procedure produces a standardized 
normal variable, i.e. a toxicity score with a mean of zero and a standard deviation of one. By doing so, a measure is 
obtained of where the patient’s toxicity score fits into the sensitivity spectrum of his or her original study cohort. 
Patients having a toxicity score that was in the right-hand tail of the distribution would be assigned a relatively high Z 
score whereas a patient with a score close to the population average for the endpoint in question would be assigned a 
Z score close to zero.  
 
Calculation of STAT and Z STAT scores 
Standardized Total Average Toxicity (STAT) scores [31] were calculated for each patient by taking the mean of the 
(non-missing) Z scores for different endpoints, thereby providing an overall measure of the patient’s 
radioresponsiveness. STAT scores were calculated for overall toxicity (STAT global), acute toxicity (STAT acute) and late 
toxicity (STAT late).  
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For some of the cohorts, the STAT scores were based on only one or a few toxicity recordings whereas for others 
numerous recordings were used for the calculation. The distribution of the mean STAT score depends on the number 
of toxicity items used in forming the average (i.e. STAT scores derived from a large number of observations tend to 
have smaller standard deviations than STAT scores derived from a single or few toxicity recordings).  To produce a 
standardized variable, we converted the STAT scores into Z scores (hereafter termed Z STAT). In this way, all Z scores 
and Z STAT scores have a common format characterized by a mean of zero and a standard deviation of one, making 
them directly comparable across different endpoints and cohorts.  
 
Statistical test of the association between genotype and normal tissue toxicity 
 
Analysis based on Z STAT scores and Z scores  
For each of the three possible ATM rs1801516 genotypes we calculated the means of Z STAT global, Z STAT acute, Z 
STAT late, Z acute skin, Z acute rectal, Z telangiectasia, Z fibrosis and Z late rectal. Statistical significance was evaluated 
using the non-parametric Mann–Whitney U test (Wilcoxon rank-sum test) comparing carriers of one or two minor 
alleles with the common allele homozygotes. In addition, statistical significance was tested using Spearman’s rank 
correlation coefficient as a test for trend over all three possible SNP genotypes. 
 
Analysis of odds ratios for having a score in the upper quartile 
In order to provide a measure of radiosensitivity that is easier to translate into a clinical context, we calculated odds 
ratios for having a Z STAT or Z score in the upper quartile comparing carriers of one or two minor alleles with the 
common allele homozygotes. Since the data typically had many ties, the proportion of patients having a score in the 
upper quartile occasionally deviated from 25%. The data were meta-analyzed and Forest plots created using the 
DerSimonian-Laird random effects-model [32]. The I-squared test was used to test for heterogeneity between cohorts 
[33]. Funnel plots [34] and Peters test for ‘small study effects’ [35] were used to test for indications of publication bias. 
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Multivariate analysis, calculation of residuals and analysis of odds ratios for having a residual in the upper quartile 
As mentioned previously, information on covariates with potential impact on normal tissue outcome was available for 
13 of the cohorts. For each of these cohorts, ordinal logistic regression was used to test for associations between the 
recorded patient and treatment related factors and the 8 toxicity scores. The tested covariates together with 
regression coefficients and p-values are listed in Supplementary Table S2. Multivariate analysis of the Z STAT and Z 
scores with the rs1801516 genotype was then performed on each cohort, including covariates associated with the 
toxicity score on univariate analysis with a p-value <0.2. For covariates that were closely related (e.g. various dose 
volume parameters for the same organ), the most significant one was chosen for the multivariate analysis. After 
multivariate analysis, residuals were calculated for each patient, for the STAT and Z scores (hereafter termed R-STAT 
and R-Z scores respectively). The analysis war carried out using STATA (StataCorp, Chicago, USA).  A residual is the 
difference between the observed and the estimated toxicity score and provides a measure of the toxicity not 
explained by available patient and treatment related factors. Patients with residuals of zero have toxicity entirely 
accounted for by these factors. Patients with negative or positive residuals have less or greater toxicity respectively 
than is explained by known factors. In parallel with the analysis of the Z STAT and Z scores, we calculated odds ratios 
for having an R- STAT or R-Z score in the upper quartile comparing carriers of one or two minor alleles with the 
common allele homozygotes. The data were meta-analyzed and Forest plots created using the Der-Simonian-Laird 
random effects-model [32].  
 
Results 
 
Genotype distribution 
The genotype distribution of the patients included in the analysis is shown in Supplementary Table S3. Approximately 
76% were common allele homozygotes, 22% were heterozygotes whereas just below 2% were minor allele 
homozygotes. This corresponds to a MAF of 12.9%. These results are consistent with those reported in other studies 
and the genotype distribution did not deviate from Hardy Weinberg equilibrium using a significance threshold of 0.01.   
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Analysis based on Z STAT scores and Z scores  
Figure 1 shows the mean Z STAT and Z scores as per genotype for the eight toxicity endpoints.  Generally, patients 
with the variant allele had higher toxicity scores. The results were mostly consistent with a co-dominant pattern of 
inheritance. Furthermore, the strongest associations were observed for acute endpoints. Using the Mann–Whitney U 
test (Wilcoxon rank-sum test) as well as the Spearman rank correlation test, significant results were obtained for Z 
STAT global, Z STAT acute, Z STAT late, Z acute skin and Z acute rectal. For Z telangiectasia and Z fibrosis, the results 
did not reach statistical significance with p-values around 0.1. However, the results had the same direction as those 
reaching statistical significance.  For late rectal toxicity, the analysis did not provide any indication that the SNP affects 
the normal tissue complication risk.  
 
Analysis of odds ratios for having a score in the upper quartile 
Figure 2 shows the Forest and funnel plots for the meta-analysis of the odds ratios for having a Z STAT global score in 
the upper quartile comparing patients with one or two minor alleles with the common allele homozygotes. 
Supplementary Figure S2 shows the Forest plots and funnel plots for the other endpoints. Table 2 provides a summary 
of the meta-analysis odds ratios for the 8 endpoints.  In this analysis, significant associations were found for five of 
these endpoints but not for Z STAT late, Z acute rectal and Z late rectal.  Generally, the associations were stronger for 
acute endpoints (with odds ratios around 1.5) than for the late endpoints (with odds ratios around 1.2). The I-squared 
test did not provide indications of significant heterogeneity between the cohorts for any of the endpoints. The funnel 
plots and Peters test for ‘small study effects’ did not provide indications of publication bias (Figure 2 and 
Supplementary Figure S2).  
 
Multivariate analysis, calculation of residuals and analysis of odds ratios for having a residual in the upper quartile 
Figure 3 shows the Forest and funnel plots for R-STAT global. Supplementary Figure S3 shows the Forest plot and 
funnel plots for the other endpoints. Table 2 provides an overview of the meta-analysis results.  The adjustment for 
the included covariates only slightly altered the results compared to the unadjusted scores. Only the associations for 
R-STAT global, R-STAT acute and R-Z acute skin reached statistical significance.  
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Discussion 
 
Methodological aspects 
 
The primary strength of the present study is its very large sample size. Furthermore, the data were analyzed at the 
level of the individual patient and adjustments were made for treatment related factors with potential impact on 
toxicity risk. With more than 5,000 patients included in the analysis and a total number of toxicity recordings 
exceeding 30,000, the study is by far the largest of its kind. Nevertheless, this came at the expense of the cohorts 
included in the analysis being rather heterogeneous. Particularly for the STAT scores, very diverse data were pooled 
for the analysis. In order to allow for a comparison across different endpoints, scoring systems, treatment regimens 
and institutions, we converted the toxicity data into Z-scores. This method is generally accepted as a pragmatic 
solution to the problems that relate to heterogeneous study cohorts (31) and has often been used in collaborative 
radiogenomics studies (e.g. [6,13,14] and [30]). Furthermore, the method mitigates the so-called centre effect [36] 
wherein the institution at which the patient was treated may act as a confounder. Concerning the multivariate 
analysis, it was reassuring that the covariates included in the multivariate linear regression model were often factors 
known to affect the risk of normal tissue toxicity (such as body mass index/breast size, radiation dose and 
fractionation). Nevertheless, the adjustments made for these covariates only altered the results marginally. Since 
recordings of treatment and patient related covariates were only available for some of the cohorts, the number of 
patients included in the multivariate analysis was somewhat reduced. Presumably due to this, fewer of the findings 
reached statistical significance. The present meta-analysis included published as well as unpublished patient series. 
The funnel plots showed no obvious signs of publication bias, and the Peters test for ‘small study effects’ was negative 
for all the meta-analyses conducted. It is therefore unlikely that the results are significantly affected by publication 
bias.  One base downstream of the rs1801516 a SNP designated rs1801673 (c.5558A>T, p.Asp1853Val) is located. This 
SNP is relatively rare with a minor allele frequency below 1% and was not taken into account in our meta-analysis. Our 
meta-analysis involved multiple comparisons. Despite this, we did not adjust for multiple testing. In most instances, 
the tests were not statistically independent and a standard adjustment for multiple comparisons would therefore be 
overly conservative. Furthermore, there was a high degree of consistency of the results across endpoints that were 
ATM rs1801516 SNP and toxicity after radiotherapy 
 
11 
 
not scored in the same patients. Consequently, we consider it highly unlikely that the positive findings of our meta-
analysis could be the result of random fluctuations due to multiple testing.  
 
Interpretation of the results 
The present meta-analysis shows, with a high level of confidence, that the ATM rs1801516 SNP is associated with risk 
of normal tissue toxicity after radiosensitivity. Furthermore, the analysis indicates that the SNP has a stronger 
association with acute than late toxicity. The results are indicative of a co-dominant pattern of inheritance. With an 
odds ratio around 1.3, the phenotypic impact of this SNP is fairly small. This observation is in agreement with the 
results of many genome wide association studies (GWAS) addressing various biomedical phenotypes in which most of 
the identified SNPs only had a modest impact on phenotype [1,37,38]. The effect size of the rs1801516 SNP 
demonstrated by our meta-analysis is below the detectable effect size in the radiogenomics GWASs published so far 
(2-8). Furthermore, the small effect size explains why the candidate gene studies conducted did not report consistent 
findings for this SNP [19-21]. As mentioned in the introduction, three literature based meta-analyses have addressed 
the impact of the rs1801516 SNP upon risk of normal tissue toxicity after radiotherapy. One of these included 2,127 
patients from 12 cohorts and addressed normal tissue toxicity in a broader sense [19]. The patients were treated for 
breast, prostate and head and neck cancer and investigated a mixture of different acute and late normal tissue 
reactions. This study did not show any significant association between the rs1801516 SNP and normal tissue outcome. 
Nevertheless, with a per-allele odds ratio of 1.11 (95% CI 0.77-1.59) for the Asn allele, our value is within the 95% 
confidence interval of the meta-analysis. Another meta-analysis included 1,588 patients from 5 different cohorts and 
addressed acute reactions after radiotherapy for prostate and breast cancer [20]. Consistent with our findings, this 
study reported an odds ratio of 1.33 (95%CI 1.04-1.77) for carriers of the minor (Asn) allele. The most recent meta-
analysis included 2,000 patients from 9 different cohorts [21]. The patients were given radiotherapy for breast cancer, 
prostate cancer, head and neck cancer and brain tumours. This study addressed radiation-induced fibrosis. In 
agreement with our analysis, it showed a significantly increased risk of fibrosis (OR = 1.78, 95% CI: 1.07, 2.94) among 
carriers of the Asn allele. It should, however, be noted that all these meta-analyses had a number of cohorts in 
common with our study. 
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The rs1801516 SNP is located in a highly conserved element in the ATM gene (LOD score 250)(Supplementary Text 
File 2). It results in a non-conservative amino acid substitution from the acidic aspartic acid to the polar asparagine 
at codon 1853 in exon 37 (NM_000051.3). Thus, the SNP may potentially have a functional impact. Nevertheless, 
the SNP is classified as ‘benign’ by several different missense prediction algorithms (Align GVGD, SIFT, NCBI ClinVar 
and PROVEAN) (Supplementary Text File 2). Likewise, no change in natural splice sites is predicted by several 
splicing prediction tools (Splice Sequence Finder, MaxEntScan, NNSplice, and Human Splicing Finder).  A cryptic and 
alternative acceptor splice site, located at the nucleotide 5558, is predicted to be removed by the rs1801516 SNP 
minor allele (Supplementary Text File 2).  However, the consequence of this on alternative splicing is unknown. To 
our knowledge, only one study has investigated the functional impact of the rs1801516 SNP [39]. In this study, no 
significant differences were observed in the constitutive ATM protein level, cell survival or TP53 protein induction 
after radiation in vitro of lymphoblastoid cell lines from patients with each of the three possible rs1801516 SNP 
genotypes. Nevertheless, these investigations only included ‘a limited number of patients’ [39] and were therefore 
probably not powered to detect small differences in these parameters.  The rs1801516 SNP is in linkage 
disequilibrium with numerous other SNPs [40]( Supplementary Text File 2). Consequently, it cannot be ruled out 
that the SNP acts as a tagging SNP for another sequence variant with functional impact. Heterozygosity for a 
truncating mutation in ATM is a well-known risk factor for breast cancer [38].  Given that the rs1801516 SNP has a 
functional impact (or tags a variant with functional impact), one could expect this SNP to affect breast cancer risk. 
However, even though breast cancer susceptibility has been investigated in several very large GWASs that were 
powered to detect small effect sizes, the rs1801516 SNP was not identified as a risk factor [38]. Nor did a large 
meta-analysis (N=7,971) provide evidence that the rs1801516 affects breast cancer risk [40]. A search in the NHGRI-
EBI GWAS database (http://www.ebi.ac.uk/gwas/) identifies only one hit for the rs1801516 SNP. This involves a 
large multi-centre GWAS with several replication cohorts addressing risk of malignant melanoma [41]. This study 
included a total of 10,422 subjects and identified an association for the rs1801516 SNP that reached genome wide 
significance with a p-value of 3.4 x 10
-9
. Nevertheless, in this study the minor allele was protective with an odds ratio 
of 0.84. A more recent meta-analysis of data from 11 GWASs addressing malignant melanoma with a total of 15,990 
cases and 26,409 controls confirmed the association with a p value of 6.6 x 10
-12
 [42]. As mentioned previously, the 
gene product of ATM is involved in the detection of DNA double strand breaks and initiation of pathways that leads 
to cell cycle arrest followed by DNA repair or apoptosis [15]. Thus, ATM plays a crucial role in the biological response 
to ionizing radiation and influences the fate of the cell following irradiation [16]. Acute radiation toxicity typically 
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takes place in skin or mucosal membranes and its pathogenesis is assumed to involve depletion of rapidly dividing 
cells in the basal layer [12].  In our meta-analysis, the rs1801516 SNP had a stronger impact on acute than late 
toxicity. Based on these observations, it can be hypothesized that the Asn allele in codon 1853 (or another variant 
tagged by this allele) may result in an increased tendency to cell cycle arrest or apoptosis. This would possibly lead 
to increased acute toxicity but at the same time be protective against radiation-induced malignancy. Our meta-
analysis shows that it is possible to extract useful information from study cohorts that are very heterogeneous. 
However, it does at the same time illustrate the methods and large sample sizes required to detect a relatively weak 
signal in a noisy dataset. Thus, our study warrants further cooperative research initiatives in radiogenomics. 
 
Conclusion 
This very large individual patient data meta-analysis conducted by the RgC provides convincing evidence of an 
association between the Asn allele in the ATM rs1801516 SNP and an increased risk of normal tissue toxicity after 
radiotherapy with and odds ratio of approximately 1.5 for acute toxicity and 1.2 for late toxicity. The findings of this 
study warrant research into the functional impact of this SNP (or another sequence variant tagged by this SNP). In 
addition, further large studies quantifying the effect size of this SNP in the setting of a less heterogeneous study 
population should be encouraged.  
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Table 1. Data included from each cohort with total number of observations (Obs) and number of patients (Ptn). (b) = breast cohort. (p) = prostate cohort. Ref. indicates the reference in which the cohort is described. †indicates cohorts 
from which data on covariates with potential impact on the normal tissue outcome were available. *indicates that the rs1801516 SNP was indirectly genotyped by means of the rs4988023 SNP. 
                    
                           
    STAT global  STAT acute  acute skin  Acute rectal  STAT late  Telengiectasia Fibrosis  Late rectal 
Cohort Ref.  N (all) Obs Ptn  Obs Ptn  Obs Ptn  Obs Ptn  Obs Ptn  Obs Ptn  Obs Ptn  Obs Ptn 
CIHR1 (b)† 14  158 632 158           632 158  158 158  158 158    
CIHR2  (b) † 14  78 465 78           465 78  78 78  78 78    
DBCG I  (b) † 24  41 123 41  41 41  41 41     82 41  41 41  41 41    
DBCG II  (b) † 25  234 702 234  234 234  234 234     468 234  234 234  234 234    
GenePARE  (b) 8,26  179 358 179           358 179  179 179  179 179    
LeND  (b) 13  583 1,165 583           1,165 583  583 583  582 582    
MARIE RAD  (b) † 14  273 545 273           545 273  273 273  272 272    
Pre START (b) 27  52 104 52           104 52     52 52    
RAPPER  (b) †* 6  940 11,651 940  925 925  925 925     10,726 929  858 858  737 737    
SANT PAU (b) † 30  101 390 101  99 99  99 99     291 101     96 96    
VHEBRON (b) †   58 86 58  58 58  58 58     28 28     28 28    
AERT RADIOGEN (p) † 28  724 4,304 724  2,896 724     724 724  1,408 470        468 468 
CCI  (p) † 5  155 465 155           465 155        155 155 
GenePARE  (p) 5  976 1,920 976           1,920 976        970 970 
Ghent  (p) † 29  281 1,964 281  1,964 281     1.964 281             
RAPPER CHHiP  (p) †* 6  411 4,483 411           4.483 411        411 411 
RAPPER RT01  (p) †* 6  212 1,649 212           1.649 212        211 211 
All breast   2,697 16,221 2,697  1,357 1,357  1,357 1,357     14,864 2,656  2,404 2,404  2,457 2,457    
All prostate   2,759 14,785 2,759  4,860 1,005     2,688 1,005  9,925 2,224        2,215 2,215 
All   5,456 31,006 5,456  6,217 2,362  1,357 1,357  2,688 1,005  24,789 4,880  2,404 2,404  2,457 2,457  2,215 2,215 
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Table 2. Overview of the meta-analysis odds ratios for having a Z or Z STAT score or a residual of these 
scores in the upper quartile (Asp/Asp and Asp/Asn vs. Asn/Asn). Significant findings are marked in bold. 
 
Endpoint N Meta-
analysis 
OR 
95% CI  Endpoint N Meta-
analysis 
OR 
95% CI 
Z STAT global 5,456 1.20 1.04-1.38  R-STAT global 3,339 1.24 1.03-1.48 
Z STAT acute 2,362 1.49 1.17-1.88  R-STAT acute 2,300 1.51 1.21-1.88 
Z acute skin 1,357 1.71 1.11-2.66  R-Z acute skin 1,304 1.60 1.06-2.41 
Z acute rectal 1,005 1.38 0,93-2.03  R-Z acute rectal   996 1.25 0.70-2.24 
Z STAT late 4,880 1.16 0.99-1.34  R-STAT late 2,773 1.18 0.97-1.45 
Z telangiectasia 2,004 1.31 1.05-1.65  R-Z telangiectasia 1,593 1.23 0.82-1.84 
Z fibrosis 2,457 1.27 1.02-1.58  R-Z fibrosis 1,602 1.18 0.86-1.62 
Z late rectal 2,215 1.12 0.77-1.64  R-Z late rectal 1225 1.24 0. 90-1.72 
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Figure legends  
 
 
Figure 1 
Mean Z STAT and Z scores as per genotype for the eight normal tissue endpoints. Error bars indicate standard error of 
the mean (SEM). 
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Figure 2 
Forest plot and funnel plot showing the meta-analysis result for having a Z STAT global score in the upper quartile 
(Asp/Asp and Asp/Asn vs. Asn/Asn). 
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Figure 3 
Forest plot and funnel plot showing the meta-analysis result for having an R-STAT global score in the upper quartile 
(Asp/Asp and Asp/Asn vs. Asn/Asn). 
 
 
 
 
 
 
 
 
 
 
 
